A randomized clinical trial conducted in the Netherlands with 464 patients examined the effects of daily myo-inositol supplementation during pregnancy on complications in those with polycystic ovary syndrome (PCOS). Results indicated similar rates of major complications, including gestational diabetes, preeclampsia, and preterm birth between the myo-inositol and placebo groups, with adverse events occurring at comparable rates. Some limitations noted include higher baseline biochemical hyperandrogenism in the myo-inositol group and lower-than-anticipated event rates, potentially affecting statistical power.

Source: JAMA